利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.01 秒)

    Multi-Phase Contraceptive Preparation Based on a Natural Estrogen
    1.
    发明申请
    Multi-Phase Contraceptive Preparation Based on a Natural Estrogen 有权
    基于天然雌激素的多相避孕药制剂

    公开(公告)号：US20070259840A1

    公开(公告)日：2007-11-08

    申请号：US11578771

    申请日：2005-04-15

    申请人： Jan Endrikat ,  Bernd Duesterberg

    发明人： Jan Endrikat ,  Bernd Duesterberg

    IPC分类号： A61K31/566 ,  A61K31/565 ,  A61P15/18

    CPC分类号： A61K31/57 ,  A61K31/00 ,  A61K31/56

    摘要： The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

    摘要翻译： 具有较高避孕安全性和降低副作用的多相制剂是基于天然雌激素与地诺酮或屈螺酮的组合。 多相制剂的特征在于第一阶段由2日剂量单位的3mg雌二醇戊酸酯组成，第二相由两组日剂量单位组成，其中第一组由5个每日剂量单位形成，每个剂量单位包含 2mg戊酸雌二醇酯和至少两次或三次排卵抑制剂量的依诺孕酮或屈螺酮和第二组由17个日剂量单位形成，每个剂量单位含有2mg戊酸雌二醇的组合和至少三或四次 止吐剂或屈螺酮的排卵抑制剂量，第三阶段由2mg日间剂量单位的1mg戊酸雌二醇组成，另外一个阶段由2个每日剂量单位的药学上可接受的安慰剂组成。

    MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN
    2.
    发明申请
    MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN 审中-公开
    基于自然雌激素的多阶段合同准备

    公开(公告)号：US20110124612A1

    公开(公告)日：2011-05-26

    申请号：US13020913

    申请日：2011-02-04

    申请人： Jan ENDRIKAT ,  Bernd Duesterberg

    发明人： Jan ENDRIKAT ,  Bernd Duesterberg

    IPC分类号： A61K31/565 ,  A61P15/18

    CPC分类号： A61K31/57 ,  A61K31/00 ,  A61K31/56

    摘要： The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

    摘要翻译： 具有较高避孕安全性和降低副作用的多相制剂是基于天然雌激素与地诺酮或屈螺酮的组合。 多相制剂的特征在于第一相由3mg戊酸雌二醇的2个日剂量剂量单位组成，第二相由2组日剂量单位组成，其中第一组由每日含5个组合的每日剂量单位形成 的2mg戊酸雌二醇酯和至少两次或三次排卵抑制剂量的依诺孕酮或屈螺酮，第二组由17个日剂量单位形成，每个剂量单位含有2mg戊酸雌二醇的组合和至少三次或四次 二烯酸或屈螺酮的排卵抑制剂量，第三阶段由1mg戊酸雌二醇的2个每日剂量单位组成，另外的阶段由药物可接受的安慰剂的2个每日剂量单位组成。

    Multi-phase contraceptive preparation based on a natural estrogen
    4.
    发明授权
    Multi-phase contraceptive preparation based on a natural estrogen 有权
    基于天然雌激素的多阶段避孕药

    公开(公告)号：US08071577B2

    公开(公告)日：2011-12-06

    申请号：US11578771

    申请日：2005-04-15

    申请人： Jan Endrikat ,  Bernd Duesterberg

    发明人： Jan Endrikat ,  Bernd Duesterberg

    IPC分类号： A61K31/56

    CPC分类号： A61K31/57 ,  A61K31/00 ,  A61K31/56

    摘要： The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

    摘要翻译： 具有较高避孕安全性和降低副作用的多相制剂是基于天然雌激素与地诺酮或屈螺酮的组合。 多相制剂的特征在于第一阶段由2日剂量单位的3mg雌二醇戊酸酯组成，第二相由2组日剂量单位组成，其中第一组由5个每日剂量单位形成，每个剂量单位包含 2毫克戊酸雌二醇和至少两次或三次排卵抑制剂量的依诺孕酮或屈螺酮和第二组由17个日剂量单位形成，每个剂量单位含有2mg戊酸雌二醇的组合和至少三或四次 排斥抑制剂量的地诺酮或屈螺酮，第三阶段由2毫克每日剂量单位的1毫克戊酸雌二醇组成，另一个阶段由2个每日剂量单位的药学上可接受的安慰剂组成。

    Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
    6.
    发明申请
    Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same 审中-公开
    口服避孕和口服治疗功能障碍性子宫出血的组合制剂，含有戊酸雌二醇和dienogest及其使用方法

    公开(公告)号：US20070088011A1

    公开(公告)日：2007-04-19

    申请号：US11377693

    申请日：2006-03-16

    申请人： Susan Zeun ,  Pol Boudes ,  Angelo Secci ,  Jan Endrikat ,  Holger Zimmermann

    发明人： Susan Zeun ,  Pol Boudes ,  Angelo Secci ,  Jan Endrikat ,  Holger Zimmermann

    IPC分类号： A61K31/57 ,  A61K31/56

    CPC分类号： A61K31/56 ,  A61K31/57

    摘要： The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate; a second phase of two groups of daily dosage units, which consist of a first group containing 5 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 2 mg of dienogest, and a second group containing 17 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily dosage units each consisting of 1 mg of estradiol valerate; and another phase of 2 daily dosage units of a pharmaceutically harmless placebo; so that the multiphase combination preparation consists of a total number of 28 daily dosage units.

    摘要翻译： 用于口服功能障碍性子宫出血和口服避孕药物的多相组合制剂含有2个日剂量单位的第一阶段，每个剂量单位由3mg戊酸雌二醇组成; 两组每日剂量单位的第二期，由含有5个日剂量单位的第一组组成，每组含有2mg戊酸雌二醇和2mg的二烯酸的组合，第二组含有17个日剂量 单位，其中每一个由2mg戊酸雌二醇和3mg的二烯酸的组合组成; 第三阶段为每日2剂量单位，每组1公斤戊酸雌二醇; 另一阶段是药物无害安慰剂的2个日剂量单位; 使多相组合制剂共计28个日剂量单位。

    Menstrual cycle control and improvement of conception rates in females
    7.
    发明申请
    Menstrual cycle control and improvement of conception rates in females 审中-公开
    月经周期控制和女性受孕率的提高

    公开(公告)号：US20050171071A1

    公开(公告)日：2005-08-04

    申请号：US11027690

    申请日：2005-01-03

    申请人： Jan Endrikat ,  Bernd Duesterberg ,  Jens Wessel ,  Ilka Schellschmidt

    发明人： Jan Endrikat ,  Bernd Duesterberg ,  Jens Wessel ,  Ilka Schellschmidt

    IPC分类号： A61K31/565 ,  A61K31/567 ,  A61K31/57 ,  A61K31/585 ,  A61K31/56

    CPC分类号： A61K31/567 ,  A61K31/565 ,  A61K31/57 ,  A61K31/585 ,  A61K2300/00

    摘要： The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and/or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days to 35 days or multiple periods thereof. Furthermore, the invention relates to the combination of at least one estrogen and at least one progestin for the preparation of a medicament to be used in the abovementioned indications. A pharmaceutical kit, according to the invention, comprises 21 to 35 dosage units or a multiple of 21 to 35 dosage units, wherein a first section comprises at most 21 dosage units of at least one estrogen; and a second section comprises from 2 to 34 dosage units of at least one estrogen and from 2 to 34 dosage units of at least one progestin or comprises from 2 to 34 dosage units of at least one estrogen and at least one progestin provided that in each dosage unit containing a progestin or a progestin and an estrogen the progestin is in a non-ovulation inhibiting amount; and and optionally a third section comprises at most 10 dosages of a pharmaceutically acceptable placebo or a blank.

    摘要翻译： 本发明涉及增加受孕可能性，治疗低繁殖力和/或提供月经周期控制而不抑制女性排卵的方法，包括在治疗期内施用有效剂量的至少一种雌激素和至少一种孕激素 至少21天至35天或多个周期。 此外，本发明涉及至少一种雌激素和至少一种孕激素的组合，用于制备用于上述适应症的药物。 根据本发明的药物试剂盒包含21至35个剂量单位或21至35个剂量单位的倍数，其中第一部分包含至多21个剂量单位的至少一种雌激素; 并且第二部分包含2至34个剂量单位的至少一种雌激素和2至34个剂量单位的至少一种孕激素，或包含2至34个剂量单位的至少一种雌激素和至少一种孕激素，条件是每个 含有孕激素或孕激素和雌激素的剂量单位，孕激素处于非排卵抑制量; 和任选的第三部分包含至多10个剂量的药学上可接受的安慰剂或空白。

    MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN
    8.
    发明申请
    MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN 审中-公开
    基于自然雌激素的多阶段合同准备

    公开(公告)号：US20100173877A1

    公开(公告)日：2010-07-08

    申请号：US12726799

    申请日：2010-03-18

    申请人： Jan Endrikat ,  Bernd Duesterberg

    发明人： Jan Endrikat ,  Bernd Duesterberg

    IPC分类号： A61K31/56 ,  A61P15/18

    CPC分类号： A61K31/57 ,  A61K31/00 ,  A61K31/56

    摘要： The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

    摘要翻译： 具有较高避孕安全性和降低副作用的多相制剂是基于天然雌激素与地诺酮或屈螺酮的组合。 多相制剂的特征在于第一相由3mg戊酸雌二醇的2个日剂量剂量单位组成，第二相由2组日剂量单位组成，其中第一组由每日含5个组合的每日剂量单位形成 的2mg戊酸雌二醇酯和至少两次或三次排卵抑制剂量的依诺孕或屈螺酮，第二组由17个日剂量单位形成，每个剂量单位含有2mg戊酸雌二醇的组合和至少三或四次 二烯酸或屈螺酮的排卵抑制剂量，第三阶段由1mg戊酸雌二醇的2个每日剂量单位组成，另外的阶段由药物可接受的安慰剂的2个每日剂量单位组成。

    Extended use combination comprising estrogens and progestins
    10.
    发明申请
    Extended use combination comprising estrogens and progestins 审中-公开
    延长使用组合，包括雌激素和孕激素

    公开(公告)号：US20050113350A1

    公开(公告)日：2005-05-26

    申请号：US10721825

    申请日：2003-11-26

    申请人： Bernd Duesterberg ,  Jan Endrikat ,  Rolf Schuermann

    发明人： Bernd Duesterberg ,  Jan Endrikat ,  Rolf Schuermann

    IPC分类号： A61K31/56

    CPC分类号： A61K31/56

    摘要： A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.

    摘要翻译： 一种用于在所需时间长于21-28天获得连续激素治疗的药物制剂，其包含含有至少一种雌激素和/或至少一种孕激素的预定量的第一组合物，其在前21-28天 天和第二组合物，其含有高于第一组合物的量的预定量的至少一种雌激素和/或至少一种孕激素，并且包含药物剂量的单相或多相序列。